CDK4 and non-small cell lung carcinoma: For instance, in a phase 1b study of NSCLC, Pujol et al. warned that patients treated with a CDK4/6i (abemaciclib) and an immune checkpoint inhibitor (pembrolizumab) simultaneously tended to develop a higher rate of transaminase elevations and pneumonitis compared with previous reports [138].